Giredestrant (WILSERDLY) — Drug Intelligence Dossier
A medicinal-chemistry dossier on giredestrant (WILSERDLY) — the first oral SERD approved with everolimus for ER+/HER2−, ESR1-mutated advanced breast cancer: mechanism, the crystallization-driven Pictet–Spengler manufacturing route, key intermediates, and the evERA data.
Read article →